Medicine consulting firm DeciBio Consulting reported on Thursday the availability of the Emmes SARS-CoV-2 Testing Database that includes diagnostic and serology testing details at hospital, public health, commercial reference labs, as well as send-out volumes.
According to the company, the DeciBio Emmes SARS-CoV-2 Testing Database reportedly provides data visualization tools and raw data covering coronavirus testing practices in approximately 400 labs in the US. The database and easy-to-navigate visualization suite are available on a subscription basis for clients in sales, development, strategic, investment analytics / market research and operations roles.
This database is latest addition to the market intelligence products including the Emmes Infectious Disease Database, the Emmes Oncology Database, BioMAP (immuno-oncology biomarkers), Marketbooks, Dexter and BioTrack under DeciBio Consulting's umbrella. The database collects information on platforms and kits used, sample collection devices, co-testing behaviors and more.
The company said the preliminary results indicate nearly half of labs have reported that kit availability fails to meet demand, one third of surveyed labs use multiple platforms testing at these labs and account for total volumes for the database, some labs have reported reduced operational hours affecting testing outputs and the serology test adoption is beginning to mature but lags behind diagnostic testing.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients